Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib

Proteasome inhibitors have become an integral part of myeloma therapy. Considerable efforts have gone into optimizing this therapeutic approach to obtain maximal proteasome inhibition with least toxicity. Ixazomib is the first oral proteasome inhibitor to enter the clinic and has been studied as a s...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood
Main Authors: Kumar, Shaji K., LaPlant, Betsy R., Reeder, Craig B., Roy, Vivek, Halvorson, Alese E., Buadi, Francis, Gertz, Morie A., Bergsagel, P. Leif, Dispenzieri, Angela, Thompson, Melanie A., Crawley, Jamie, Kapoor, Prashant, Mikhael, Joseph, Stewart, Keith, Hayman, Suzanne R., Hwa, Yi L., Gonsalves, Wilson, Witzig, Thomas E., Ailawadhi, Sikander, Dingli, David, Go, Ronald S., Lin, Yi, Rivera, Candido E., Rajkumar, S. Vincent, Lacy, Martha Q.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2016
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5114487/
https://ncbi.nlm.nih.gov/pubmed/27702799
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2016-05-717769
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados